J&J
NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis
April 27, 2016Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation
The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …
Focus: Ovarian cancer and the case of elusive cure
April 12, 2016Research and Development J&J, JJ, Pfizer, drug trials, ovarian cancer
Each year, more than 21,000 women in the US are diagnosed with ovarian cancer, according to research and more than …
Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million
April 6, 2016Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research
Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …
J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease
March 18, 2016Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease
Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …
FDA strengthens safety warning for J&J’s diabetes drug Invokana
September 14, 2015Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes
Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …
Janssen sales follow J&J’s downward trend
July 15, 2015Sales and Marketing J&J, JJ, Johnson & Johnson, Johnson and Johnson, financial results, olysio
Strong sales of its new hepatitis C treatment Olysio were not enough to stop a slump in profits at J&J’s …
J&J to file 10 new key drugs by 2019
May 21, 2015Sales and Marketing J&J, JJ
Johnson & Johnson says it plans to file 10 new products with regulators between 2015 and 2019 with each having …
FDA issues more diabetes drug warnings
May 18, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Boehringer, J&J, JJ, lilly
The FDA has warned that a class of type 2 diabetes drugs manufactured by several big pharma firms could cause …
J&J hands over compassionate use reviews to academics
May 7, 2015Sales and Marketing J&J, JJ, academics, compac, eap, johnson
Johnson & Johnson has struck a ‘first-of-its-kind partnership’ with academic researchers to review requests for compassionate use of its investigational …
J&J strong pharma sales can’t offset Q1 losses
April 15, 2015Sales and Marketing J&J, JJ, Q1, Waldenström's macroglobulinemia, Waldenström’s Macroglobulinemia, Zytiga, abiraterone acetate, financials, ibrutinib, imbruvica
Johnson & Johnson’s pharma division achieved worldwide sales of $7.7 billion in the first quarter of this year – but …
IBM partners with J&J, Apple and Medtronics ‘to transform healthcare’
April 14, 2015Sales and Marketing Apple, J&J, JJ, ibm, medtronics
IT firm IBM has teamed up with pharma giants and tech companies to expand its presence in the health and …
J&J and Google partner to build surgical robots
March 30, 2015Medical Communications, Sales and Marketing Biogen, Ethicon, J&J, JJ, Johnson and Johnson, MS, google, robots
The medical device subsidiary of Johnson & Johnson Ethicon is to collaborate with Google to build surgical robots and perform …
J&J blood cancer drug gets UK launch
March 25, 2015Sales and Marketing Cancer, J&J, JJ, Janssen, NICE, Velcade, bortezomib, mcl, nhl
Johnson and Johnson’s pharma unit Janssen is launching Velcade in the UK for the first-line treatment of Mantle Cell Lymphoma …
J&J acquires Index Ventures-owned firm XO1
March 23, 2015Sales and Marketing Index Ventures, Isis, J&J, JJ, Janssen, vectura, xo1
Johnson & Johnson’s pharma unit Janssen has acquired Index Ventures’ biopharma firm XO1 Limited that develops the promising anti-thrombin antibody …
Big pharma partners with government over $100m dementia fund
March 17, 2015Research and Development, Sales and Marketing Alzheimer's, Biogen IDEC, GSK, J&J, JJ, Pfizer, government, jp morgan, lilly
Lilly, Pfizer, GSK, J&J and Biogen Idec are set to join a $100m Dementia Discovery Fund to boost research into …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
